A randomised, assessor-blind, active-controlled, parallel-group, dose-finding trial to investigate the efficacy and safety of FE 999302 for triggering of final follicular maturation in women undergoing controlled ovarian stimulation
Latest Information Update: 22 May 2023
Price :
$35 *
At a glance
- Drugs Chorionic gonadotropin (Primary) ; Choriogonadotropin alfa
- Indications Infertility
- Focus Therapeutic Use
- Acronyms TIFFANY
- Sponsors Ferring Pharmaceuticals
- 22 May 2023 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
- 21 Jan 2023 This trial has been discontinued in Czech Republic (End Date: 13 Dec 2022) according to European Clinical Trials Database record.
- 05 Jan 2023 Status changed from suspended to withdrawn prior to enrolment. Based on company decision to close the project. No trial participants received any study drug.